IR@PKUHSC  > 北京大学第一临床医学院  > 药剂科
学科主题临床医学
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
Zhao, Xia1; Sun, Peihong1; Zhou, Ying1; Liu, Yuwang1; Zhang, Huilin1; Mueck, Wolfgang3; Kubitza, Dagmar3; Bauer, Richard J.4; Zhang, Hong2; Cui, Yimin1
关键词Anticoagulant Chinese Subjects Factor Xa Inhibitor Rivaroxaban
刊名BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
2009-07-01
DOI10.1111/j.1365-2125.2009.03390.x
68期:1页:77-88
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]TOTAL HIP-REPLACEMENT ; DEEP-VEIN THROMBOSIS ; VENOUS THROMBOEMBOLISM ; BAY 59-7939 ; ATRIAL-FIBRILLATION ; BAY-59-7939 ; PREVENTION ; ANTICOAGULATION ; PREVALENCE ; ISSUES
英文摘要

center dot Rivaroxaban is an oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.

center dot In single- and multiple-dose Phase I studies in White subjects, rivaroxaban was safe and demonstrated predictable, dose-dependent pharmacokinetics and pharmacodynamics.

WHAT THIS STUDY ADDS

center dot The Phase III programme with rivaroxaban is being conducted worldwide.

center dot Therefore, it is necessary to determine whether the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban are altered in patients of different ethnic origins.

center dot Dose-escalation studies were conducted to determine the safety, pharmacokinetics and pharmacodynamics of single and multiple doses of rivaroxaban in healthy Chinese subjects.

AIMS

To investigate the safety, pharmacokinetics and pharmacodynamics of rivaroxaban, an oral, direct Factor Xa (FXa) inhibitor, in healthy, male Chinese subjects.

METHODS

Two randomized, single-blind, placebo-controlled, dose-escalation studies were conducted in healthy Chinese men aged 18-45 years. In the single-dose study, subjects received single, oral doses of rivaroxaban 2.5, 5, 10, 20 and 40 mg. In the multiple-dose study, oral rivaroxaban was administered in doses of 5, 10, 20 and 30 mg twice daily for 6 days.

RESULTS

Rivaroxaban, in single and multiple doses up to 60 mg, was well tolerated. Rapid absorption was observed in both studies (time to C(max) 1.25-2.5 h). In the multiple-dose study, rivaroxaban exposure increased dose-proportionally after the first dose and at steady state (for the 5-20-mg doses). The half-life of rivaroxaban was up to 7.9 h in the single-dose study. Maximal inhibition of FXa activity was achieved within 1-3 h of dosing in the single-dose study [at 20 mg FXa inhibition as a median percentage change from baseline, 45.92; 95% confidence interval (CI) 44.64, 50.70] and 2-3 h after administration at steady state in the multiple-dose study (at 20 mg median FXa inhibition as a median percentage change from baseline, 60.25; 95% CI 56.16, 63.05), in line with maximum rivaroxaban plasma concentrations.

CONCLUSIONS

Rivaroxaban demonstrated predictable pharmacokinetics and pharmacodynamics in healthy Chinese subjects, in line with findings observed previously in White subjects. This suggests that fixed doses of rivaroxaban may be administered to all patients, regardless of their ethnic origin.

语种英语
WOS记录号WOS:000268050600009
资助机构Bayer Schering Pharma AG
引用统计
被引频次:38[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50519
专题北京大学第一临床医学院_药剂科
作者单位1.Bayer Schering Pharma AG, Clin Pharmacol, Wuppertal, Germany
2.Peking Univ, Hosp 1, Dept Pharm, Beijing 100034, Peoples R China
3.Bayer HealthCare Co Ltd, Dept Med, Beijing, Peoples R China
4.Bayer Schering Pharma AG, Med Affairs Asia Pacific, Wuppertal, Germany
推荐引用方式
GB/T 7714
Zhao, Xia,Sun, Peihong,Zhou, Ying,et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,2009,68(1):77-88.
APA Zhao, Xia.,Sun, Peihong.,Zhou, Ying.,Liu, Yuwang.,Zhang, Huilin.,...&Cui, Yimin.(2009).Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,68(1),77-88.
MLA Zhao, Xia,et al."Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects".BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 68.1(2009):77-88.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhao, Xia]的文章
[Sun, Peihong]的文章
[Zhou, Ying]的文章
百度学术
百度学术中相似的文章
[Zhao, Xia]的文章
[Sun, Peihong]的文章
[Zhou, Ying]的文章
必应学术
必应学术中相似的文章
[Zhao, Xia]的文章
[Sun, Peihong]的文章
[Zhou, Ying]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。